Clinical Trial Update: PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC [Phase 2]

View source ↗

Summary

A Phase 2 trial of docetaxel with prednisone and sargramostim for hormone-refractory (castration-resistant) prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)
• sargramostim (sargramostim)

Snippet

Sponsor: Veeda Oncology | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: TERMINATED